April 1, 2024
Asahi Kasei Pharma said on March 29 that it has acquired exclusive distribution rights in Japan for an additional indication of Swedish Orphan Biovitrum Japan’s (Sobi Japan) thrombopoietin receptor agonist Doptelet (avatrombopag). In Japan, Doptelet was approved in March last...read more